» Articles » PMID: 29285767

Opioid Neonatal Abstinence Syndrome: An Overview

Overview
Publisher Wiley
Specialty Pharmacology
Date 2017 Dec 30
PMID 29285767
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Opioid neonatal abstinence syndrome (NAS) refers to signs of withdrawal observed in infants experiencing intrauterine opioid exposures. Early identification of at-risk infants allows for the prompt initiation of nonpharmacologic supportive care. When withdrawal symptoms are severe despite these interventions, pharmacologic therapy including opioid weaning is initiated. Consistency with standardized nonpharmacologic approaches as well as stringent weaning protocols are important in minimizing the length of stay and length of pharmacologic treatment for these vulnerable patients.

Citing Articles

Evaluation of Administrative Data for Identifying Maternal Opioid Use at Delivery in Florida.

Elmore A, Salemi J, Kirby R, Sappenfield W, Lowry J, Dixon A Matern Child Health J. 2023; 27(Suppl 1):44-51.

PMID: 37199857 PMC: 10692249. DOI: 10.1007/s10995-023-03669-6.


Characteristics of Prescription Opioid Analgesics in Pregnancy and Risk of Neonatal Opioid Withdrawal Syndrome in Newborns.

Esposito D, Huybrechts K, Werler M, Straub L, Hernandez-Diaz S, Mogun H JAMA Netw Open. 2022; 5(8):e2228588.

PMID: 36001312 PMC: 9403776. DOI: 10.1001/jamanetworkopen.2022.28588.


Developmental Disorders and Medical Complications Among Infants with Subclinical Intrauterine Opioid Exposures.

Hall E, McAllister J, Wexelblatt S Popul Health Manag. 2018; 22(1):19-24.

PMID: 29893624 PMC: 6386081. DOI: 10.1089/pop.2018.0016.